Related Experiment Videos
A three year controlled study in children with pollinosis treated with immunotherapy
Annals of Allergy
|July 1, 1984
Summary
Specific immunotherapy (IT) proved highly effective for children with allergic rhinitis and asthma. Long-term results showed significant success rates, highlighting the benefits of IT in managing these conditions.
Area of Science:
- Allergy and Immunology
- Pediatrics
- Respiratory Medicine
Background:
- Pollen-induced allergic rhinitis and asthma are common in children.
- Specific immunotherapy (IT) is a treatment option for allergic diseases.
- Long-term outcomes of IT in pediatric populations require further investigation.
Purpose of the Study:
- To evaluate the long-term clinical effectiveness of specific immunotherapy (IT) in children with allergic rhinitis and asthma.
- To compare the outcomes of children treated with IT versus a control group receiving no IT.
- To identify factors correlating with successful IT outcomes.
Main Methods:
- Prospective, controlled study over three years.
- Inclusion of 87 children with pollen-induced rhinitis or rhinitis and asthma, all receiving specific IT.
- Inclusion of 78 control children not receiving IT.
Main Results:
- IT was successful in 94% of children with asthma and rhinitis and 90% with rhinitis (cumulative dose >80,000 PNU).
- The control group showed significantly poorer outcomes compared to the IT group.
- Successful IT outcomes correlated with highest tolerated doses and larger cumulative dosages, independent of therapy duration.
Conclusions:
- Specific immunotherapy is clinically effective for children with allergic rhinitis and asthma.
- Achieving highest tolerated and cumulative doses is crucial for successful IT outcomes.
- Further discussion is warranted regarding optimal control group management in IT studies (placebo vs. standard care).